1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Phenylketonuria (PKU) - Pipeline Review, H1 2016

Phenylketonuria (PKU) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 43 pages

Phenylketonuria (PKU) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Phenylketonuria (PKU) - Pipeline Review, H1 2016’, provides an overview of the Phenylketonuria (PKU) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Phenylketonuria (PKU), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Phenylketonuria (PKU) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU)
- The report reviews pipeline therapeutics for Phenylketonuria (PKU) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Phenylketonuria (PKU) therapeutics and enlists all their major and minor projects
- The report assesses Phenylketonuria (PKU) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Phenylketonuria (PKU)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Phenylketonuria (PKU)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Phenylketonuria (PKU) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Phenylketonuria (PKU) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Phenylketonuria (PKU) Overview 6
Therapeutics Development 7
Pipeline Products for Phenylketonuria (PKU) - Overview 7
Phenylketonuria (PKU) - Therapeutics under Development by Companies 8
Phenylketonuria (PKU) - Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Phenylketonuria (PKU) - Products under Development by Companies 11
Phenylketonuria (PKU) - Companies Involved in Therapeutics Development 12
BioMarin Pharmaceutical Inc. 12
Codexis, Inc. 13
Erytech Pharma SA 14
SOM Innovation Biotech SL 15
Synthetic Biologics, Inc. 16
Phenylketonuria (PKU) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
pegvaliase - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Recombinant Enzyme for Phenylketonuria - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Recombinant Phenylalanine-4-Hydroxylase Replacement for Phenylketonuria - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Recombinant Phenylalanine-4-Hydroxylase Replacement for Phenylketonuria - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
SOM-7400 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
SYN-200 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
SYNB-2010 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Phenylketonuria (PKU) - Recent Pipeline Updates 34
Phenylketonuria (PKU) - Dormant Projects 35
Phenylketonuria (PKU) - Product Development Milestones 36
Featured News and Press Releases 36
Jun 05, 2013: BioMarin Initiates Phase III Trial For PEG-PAL For Treatment Of Phenylketonuria 36
Sep 26, 2012: BioMarin Pharma to Initiate Phase III Program For PEG-PAL In Second Quarter Of 2013 36
Aug 02, 2010: BioMarin Reports Encouraging Preliminary Safety And Efficacy Trends In Phase II Clinical Study Of PEG-PAL In Phenylketonuria 38
Sep 22, 2009: BioMarin Initiates Phase II Clinical Study Of PEG-PAL In PKU 39
Jun 09, 2009: Results From Phase 1 Clinical Study Of PEG-PAL In PKU And Update On Phase 2 Clinical Study 39
May 20, 2008: BioMarin Initiates Phase 1 Clinical Study Of PEG-PAL In PKU 40
Nov 27, 2007: BioMarin Files Investigational New Drug Application For PEG-PAL For The Treatment Of PKU 40
May 16, 2005: BioMarin And Serono Form Strategic Alliance For The Development And Commercialization Of Phenoptin And Phenylase 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables
Number of Products under Development for Phenylketonuria (PKU), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Phenylketonuria (PKU) - Pipeline by BioMarin Pharmaceutical Inc., H1 2016 12
Phenylketonuria (PKU) - Pipeline by Codexis, Inc., H1 2016 13
Phenylketonuria (PKU) - Pipeline by Erytech Pharma SA, H1 2016 14
Phenylketonuria (PKU) - Pipeline by SOM Innovation Biotech SL, H1 2016 15
Phenylketonuria (PKU) - Pipeline by Synthetic Biologics, Inc., H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Phenylketonuria (PKU) Therapeutics - Recent Pipeline Updates, H1 2016 34
Phenylketonuria (PKU) - Dormant Projects, H1 2016 35

List of Figures
Number of Products under Development for Phenylketonuria (PKU), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Early Stage Products, H1 2016 10
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Targets, H1 2016 18
Number of Products by Stage and Targets, H1 2016 18
Number of Products by Mechanism of Actions, H1 2016 20
Number of Products by Stage and Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 22
Number of Products by Molecule Types, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N Sulphoglucosamine Sulphohydrolase ...

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.